<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992381</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00035</org_study_id>
    <nct_id>NCT00992381</nct_id>
  </id_info>
  <brief_title>Comparison Study of a New Combination of 2 Marketed Medications (Esomeprazole and Naprosyn) Versus Naprosyn Alone</brief_title>
  <official_title>A Single Centre, Two Treatment, Two Period, Two Sequence, Randomized Crossover Steady-state Relative Bioavailability Study of Naproxen in Two Tablet Formulations Given Twice Daily (PN 400 Tablets Containing 500 mg of Naproxen Plus 20 mg of Esomeprazole Versus Naprosyn® Containing Naproxen 500 mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the absorption of naproxen from the PN 400
      combination (Naprosyn and Esomeprazole) tablets is similar to that from the naproxen tablets
      (Naprosyn®), which are currently sold in Australia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the relative naproxen bioavailability of PN 400 (naproxen 500 mg plus esomeprazole 20 mg) compared to an immediate release Naprosyn® 500 mg tablet</measure>
    <time_frame>blood samples taken at various time points over 2 treatment periods of 11 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetic (PK) properties of the naproxen component of PN 400 tablet and immediate release Naprosyn® 500 mg tablet,</measure>
    <time_frame>Blood samples taken at various time point over 2 periods of 2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the adverse event profile of PN 400 with that from Naprosyn®</measure>
    <time_frame>Adverse event reporting over 2 periods of 11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PN400</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN400</intervention_name>
    <description>500mg Naproxen and 20mg esomeprazole</description>
    <arm_group_label>1</arm_group_label>
    <other_name>VIMOVO™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naprosyn</intervention_name>
    <description>500mg Naproxen</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have a body weight greater than 50 kg and BMI within the range
             18-30(inclusive).

          -  Subjects must be in good health, as assessed during pre-study medical examination and
             by review of screening results

          -  Subjects must understand the procedures involved and agree to participate in the study
             by giving fully informed, written consent

        Exclusion Criteria:

          -  Significant intercurrent disease of any type, in particular liver, kidney,
             cardiovascular disease, any form of diabetes or significant gastrointestinal disorder
             which could affect drug absorption, or any history of gastric or duodenal ulceration.

          -  Ingestion of any naproxen, omeprazole, esomeprazole or related drugs prior to the
             recruitment interview, such that these drugs will have been ingested in the 4 weeks
             prior to the day set for the first Period 1 dose
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terry Hurst</last_name>
    <role>Study Director</role>
    <affiliation>Q-Pharm Phase one unit</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jo Marjason</last_name>
    <role>Principal Investigator</role>
    <affiliation>Q-Pharm Phase one unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>MCMD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>GI Pain</keyword>
  <keyword>healthy participants</keyword>
  <keyword>Safety</keyword>
  <keyword>bioavailability</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

